Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Icon (ICLR) and Perspective Therapeutics (CATX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Harrow Health (HROW – Research Report), Icon (ICLR – Research Report) and Perspective Therapeutics (CATX – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Harrow Health (HROW)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Harrow Health today. The company’s shares closed last Thursday at $48.82.
According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of
Currently, the analyst consensus on Harrow Health is a Strong Buy with an average price target of $67.33, which is a 37.4% upside from current levels. In a report issued on February 2, William Blair also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
Icon (ICLR)
William Blair analyst Max Smock reiterated a Buy rating on Icon today. The company’s shares closed last Thursday at $85.00.
According to TipRanks.com, Smock is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Icon with a $168.67 average price target.
Perspective Therapeutics (CATX)
JonesTrading analyst Justin Walsh maintained a Buy rating on Perspective Therapeutics today and set a price target of $18.00. The company’s shares closed last Thursday at $4.86, close to its 52-week low of $2.19.
According to TipRanks.com, Walsh is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Perspective Therapeutics with a $11.80 average price target, representing a 142.8% upside. In a report issued on January 31, TipRanks – Google also upgraded the stock to Buy with a $4.50 price target.
